Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Total Voting Rights

27 Dec 2006 07:01

ReNeuron Group plc27 December 2006 27 December 2006 (ReNeuron Group plc "The Company") Total Voting Rights For the purposes of the transitional provisions of the Financial ServicesAuthority's Disclosure and Transparency Rules, the Company's total issued sharecapital at the date of this notice is £1,185,241. The Company's issued share capital consists of 118,524,100 ordinary shares of 1peach, with one voting right per share. There are no shares held in treasury. The total number of voting rights in the Company is therefore 118,524,100. The above figure of 118,524,100 may be used by shareholders as the denominatorfor the calculations by which they will determine if they are required to notifytheir interest in, or a change to their interest in, the Company, under theDisclosure and Transparency Rules. For further information contact:ReNeuron Group plcMichael Hunt, CEO Tel: 44 (0)1483 302 560 Financial DynamicsDavid Yates Tel: 44 (0)20 7831 3113Nicola Daley This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Feb 20219:55 amRNSTotal Voting Rights
15th Jan 20212:06 pmRNSSecond Price Monitoring Extn
15th Jan 20212:01 pmRNSPrice Monitoring Extension
15th Jan 20217:00 amRNSClinical Update
6th Jan 20217:00 amRNSAnalyst Conference Call
18th Dec 20204:36 pmRNSPrice Monitoring Extension
18th Dec 20207:00 amRNSNotification of Major Holdings
17th Dec 202012:44 pmRNSNotification of Major Holdings
17th Dec 20207:00 amRNSNotification of Major Holdings
17th Dec 20207:00 amRNSNotification of Allowance granted for US Patent
16th Dec 20205:37 pmRNSNotification of Major Holdings
16th Dec 20202:17 pmRNSNotification of Major Holdings
16th Dec 20207:00 amRNSNotification of Major Holdings
11th Dec 202010:33 amRNSResult of General Meeting and Total Voting Rights
11th Dec 20207:00 amRNSResult of Open Offer
25th Nov 20204:41 pmRNSSecond Price Monitoring Extn
25th Nov 20204:36 pmRNSPrice Monitoring Extension
25th Nov 20202:06 pmRNSSecond Price Monitoring Extn
25th Nov 20202:00 pmRNSPrice Monitoring Extension
25th Nov 202011:05 amRNSSecond Price Monitoring Extn
25th Nov 202011:00 amRNSPrice Monitoring Extension
24th Nov 20204:41 pmRNSSecond Price Monitoring Extn
24th Nov 20204:36 pmRNSPrice Monitoring Extension
24th Nov 20202:06 pmRNSSecond Price Monitoring Extn
24th Nov 20202:00 pmRNSPrice Monitoring Extension
24th Nov 20207:15 amRNSResult of Placing and Subscription and GM Notice
24th Nov 20207:00 amRNSInterim Results
23rd Nov 20205:42 pmRNSProposed Placing, Subscription and Open Offer
2nd Nov 20207:00 amRNSTotal Voting Rights
10th Sep 20203:59 pmRNSResult of AGM
10th Sep 20207:00 amRNSAGM Trading Update
1st Sep 20207:00 amRNSBlock Listing Review and Total Voting Rights
18th Aug 20207:00 amRNSPosting of Annual Report and Notice of AGM
12th Aug 20207:00 amRNSChanges to Non-Executive Board
3rd Aug 20207:00 amRNSTotal Voting Rights
31st Jul 20207:00 amRNSNotification of Allowance granted for US Patent
20th Jul 20207:00 amRNSPreliminary Results
14th Jul 20203:06 pmRNSNotification of Major Holdings
29th Jun 20207:00 amRNSFurther Positive Data in Retinal Clinical Trial
25th Jun 20207:00 amRNSNew Exosome Research Collaboration
17th Jun 20207:00 amRNSRegulatory Approvals and Programme Update
7th May 20207:00 amRNSCTX cell line shows further potential
7th Apr 20202:06 pmRNSSecond Price Monitoring Extn
7th Apr 20202:00 pmRNSPrice Monitoring Extension
7th Apr 202011:06 amRNSSecond Price Monitoring Extn
7th Apr 202011:00 amRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSExosome Research Collaboration
3rd Apr 20207:00 amRNSCOVID-19 Update
16th Mar 20204:43 pmRNSSecond Price Monitoring Extn
16th Mar 20204:39 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.